Progyny, Inc. (NASDAQ:PGNY) Shares Purchased by Leibman Financial Services Inc.

Leibman Financial Services Inc. boosted its position in Progyny, Inc. (NASDAQ:PGNY) by 100.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,509 shares of the company’s stock after buying an additional 31,872 shares during the period. Leibman Financial Services Inc.’s holdings in Progyny were worth $1,096,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Quarry LP increased its stake in shares of Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company’s stock worth $25,000 after acquiring an additional 836 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after buying an additional 1,246 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Progyny in the second quarter valued at approximately $44,000. Mendota Financial Group LLC acquired a new position in Progyny during the third quarter worth $56,000. Finally, Meeder Asset Management Inc. purchased a new position in Progyny in the third quarter worth $77,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Price Performance

Shares of NASDAQ PGNY opened at $20.30 on Tuesday. The company has a market cap of $1.73 billion, a PE ratio of 35.00, a price-to-earnings-growth ratio of 1.64 and a beta of 1.31. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $42.08. The company has a 50-day simple moving average of $15.75 and a 200-day simple moving average of $19.74.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same period in the prior year, the company earned $0.16 EPS. The company’s revenue was up 2.0% compared to the same quarter last year. On average, analysts anticipate that Progyny, Inc. will post 0.59 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Peter Anevski bought 209,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was bought at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the transaction, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman David J. Schlanger purchased 150,000 shares of the company’s stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the purchase, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. This trade represents a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PGNY. Leerink Partners lowered their price target on shares of Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a research note on Thursday, September 19th. Truist Financial reaffirmed a “hold” rating and issued a $19.00 target price (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Canaccord Genuity Group reduced their price objective on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a report on Wednesday, November 13th. Jefferies Financial Group decreased their target price on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. Finally, Bank of America dropped their price target on Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.